Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Cristina SuárezJames M G LarkinPoulam PatelBegoña P ValderramaAlejo Rodriguez-VidaHilary GlenFiona ThistlethwaiteChristy RalphGopalakrishnan SrinivasanMaria Jose MendezRyan HartmaierAleksandra MarkovetsAaron PrendergastBernadett SzabadosKelly MousaThomas PowlesPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The combination of savolitinib and durvalumab was tolerable and associated with high cRRs in the exploratory MET-driven subset.